NCT02262741 - A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 15, 2014

Primary Completion Date

September 21, 2017

Study Completion Date

September 21, 2017

Conditions

Squamous Cell Carcinoma of the Head and Neck

Interventions

BIOLOGICAL

MEDI4736

MEDI4736 will be administered by IV infusion in combination with tremelimumab.

BIOLOGICAL

tremelimumab

Tremelimumab will be administered by IV infusion in combination with MEDI4736.

Trial Locations (23)

10016

Research Site, New York

10065

Research Site, New York

19111

Research Site, Philadelphia

21287

Research Site, Baltimore

22031

Research Site, Fairfax

29605

Research Site, Greenville

32806

Research Site, Orlando

48201

Research Site, Detroit

55455

Research Site, Minneapolis

60611

Research Site, Chicago

66205

Research Site, Fairway

70112

Research Site, New Orleans

78229

Research Site, San Antonio

80045

Research Site, Aurora

85258

Research Site, Scottsdale

90025

Research Site, Los Angeles

90095

Research Site, Los Angeles

92093

Research Site, La Jolla

94143

Research Site, San Francisco

97213

Research Site, Portland

06520

Research Site, New Haven

N6A 4L6

Research Site, London

M5G 2M9

Research Site, Toronto